Library
A Randomized First-in-Human Study With UB-312, a UBITh® α-Synuclein Peptide Vaccine.
1 July 2022. doid: 10.1002/mds.29016
Yu HJ, Thijssen E, van Brummelen E, van der Plas JL, Radanovic I, Moerland M, Hsieh E, Groeneveld GJ, Dodart JC
View publicationα-Synuclein (αSyn) is believed to play a central role in Parkinson's disease (PD) neuropathology and is considered a target for disease modification. UB-312 is a synthetic αSyn peptide conjugated to a T helper peptide and is expected to induce antibodies specifically against oligomeric and fibrillar αSyn, making UB-312 a potential immunotherapeutic for synucleopathies.
Advancing the boundaries of clinical drug development
Wondering how we can help you? Reach out to us.
